Patients with indolent mastocytosis may express concern about anaphylaxis or milder reactions to various substances, but Dr. Aaron T. Gerds, of Cleveland Clinic, reminds them that "you can't go into a ...

The indolent lymphoma market is witnessing steady growth driven by the increasing prevalence of slow-growing non-Hodgkin lymphomas and rising awareness about early diagnosis. Additionally, the launch ...

Despite advances in chemoimmunotherapy, indolent B-cell non-Hodgkin lymphomas (B-NHLs) are generally not considered curable with this approach. Much attention has been paid to the prospect of ...

When Bob was first diagnosed and treated for follicular lymphoma, he refused to let the fear of the cancer returning dominate his life. Nearly 25 years later—after having experienced a relapse—Bob is ...

Communicating effectively with other specialists on the care team is essential, says Aaron T. Gerds, MD, MS, Associate Professor of Medicine at Cleveland Clinic Lerner College of Medicine of Case ...

Editor's note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. So, there are a number of things that set ...

In the complex world of rare diseases, even small advances in understanding can make a profound difference in patients’ lives. Medscape Live is bringing back-to-back educational programs to San Diego ...

Please provide your email address to receive an email when new articles are posted on . Axicabtagene ciloleucel induced durable responses for patients with relapsed or refractory indolent non-Hodgkin ...

For some subtypes of non-Hodgkin’s lymphoma, complete remission is possible. Doctors may refer to reaching complete remission as “curing” the cancer. According to the National Cancer Institute (NCI), ...

The indolent lymphoma market is witnessing steady growth driven by the increasing prevalence of slow-growing non-Hodgkin lymphomas and rising awareness about early diagnosis. Additionally, the launch ...